{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:43:03Z","timestamp":1784421783397,"version":"3.55.0"},"reference-count":68,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Severe respiratory syncytial virus (RSV) lower respiratory tract illness (LRTI) in infants has proven challenging to prevent. In the last 50 years, conceptually different approaches failed to evolve into viable preventive alternatives for routine use. Inactivated RSV vaccine (that is, formalin-inactivated RSV) elicited severe LRTI in RSV-infected toddlers pre-immunized as infants; early purified F protein approaches in pregnant women failed to elicit sufficient immunity more than a decade ago; a second-generation monoclonal antibody (mAb) of high potency against the virus (that is, motavizumab) caused severe adverse reactions in the skin, and owing to lack of efficacy against RSV subgroup B, an extended half-life mAb targeting site V in the RSV fusion protein (that is, REG2222) did not meet its primary endpoint. In the meantime, two protein F vaccines failed to prevent medically attended LRTI in the elderly. However, palivizumab and the recent results of the Novavax maternal immunization trial with ResVax demonstrate that severe RSV LRTI can be prevented by mAb and by maternal immunization (at least to a certain extent). In fact, disease prevention may also decrease the rates of recurrent wheezing and all-cause pneumonia for at least 180 days. In this review, we discuss the history of RSV vaccine development, previous and current vaccine strategies undergoing evaluation, and recent information about disease burden and its implications for the effects of successful preventive strategies.<\/ns4:p>","DOI":"10.12688\/f1000research.18749.1","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T09:35:24Z","timestamp":1556789724000},"page":"610","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["The long road to protect infants against severe RSV lower respiratory tract illness"],"prefix":"10.12688","volume":"8","author":[{"given":"Sofia","family":"Jares Baglivo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-9158","authenticated-orcid":false,"given":"Fernando P","family":"Polack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"422-34","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.","volume":"89","author":"H Kim","year":"1969","journal-title":"Am J Epidemiol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"449-63","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.","volume":"89","author":"J Chin","year":"1969","journal-title":"Am J Epidemiol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"405-21","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.","volume":"89","author":"A Kapikian","year":"1969","journal-title":"Am J Epidemiol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"435-48","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.","volume":"89","author":"V Fulginiti","year":"1969","journal-title":"Am J Epidemiol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"34-41","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.","volume":"15","author":"M Delgado","year":"2009","journal-title":"Nat Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"859-65","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease.","volume":"196","author":"F Polack","year":"2002","journal-title":"J Exp Med."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"189-95","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.","volume":"23","author":"P Acosta","year":"2015","journal-title":"Clin Vaccine Immunol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"e1004757","DOI":"10.1371\/journal.ppat.1004757","article-title":"RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets.","volume":"11","author":"C Knudson","year":"2015","journal-title":"PLoS Pathog."},{"key":"ref-9","doi-asserted-by":"crossref","first-page":"2032-40","DOI":"10.4049\/jimmunol.151.4.2032","article-title":"Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.","volume":"151","author":"B Graham","year":"1993","journal-title":"J Immunol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"83-104","DOI":"10.1007\/978-3-642-38919-1_4","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins.","volume":"372","author":"J McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol."},{"key":"ref-11","doi-asserted-by":"publisher","DOI":"10.1038\/srep34108","article-title":"Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus.","volume":"6","author":"A Killikelly","year":"2016","journal-title":"Sci Rep."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"137-48","DOI":"10.1038\/nri3804","article-title":"Dynamics of B cells in germinal centres.","volume":"15","author":"N De Silva","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"116-30","DOI":"10.1016\/j.immuni.2015.12.004","article-title":"A Temporal Switch in the Germinal Center Determines Differential Output of Memory B and Plasma Cells.","volume":"44","author":"F Weisel","year":"2016","journal-title":"Immunity."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"5316-22","DOI":"10.1016\/j.vaccine.2014.07.064","article-title":"Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine.","volume":"32","author":"Z Duan","year":"2014","journal-title":"Vaccine."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"108-21","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5+CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion.","volume":"34","author":"R Morita","year":"2011","journal-title":"Immunity."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"366-72","DOI":"10.1016\/j.coi.2013.04.003","article-title":"Dynamic regulation of Bcl6 in follicular helper CD4 T (Tfh) cells.","volume":"25","author":"Y Choi","year":"2013","journal-title":"Curr Opin Immunol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1359-72","DOI":"10.4049\/jimmunol.1701217","article-title":"Human Extrafollicular CD4+ Th Cells Help Memory B Cells Produce Igs.","volume":"201","author":"S Kim","year":"2018","journal-title":"J Immunol."},{"key":"ref-18","doi-asserted-by":"crossref","first-page":"7444-51","DOI":"10.1128\/JVI.66.12.7444-7451.1992","article-title":"Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of CD4+ T cells.","volume":"66","author":"M Connors","year":"1992","journal-title":"J Virol."},{"key":"ref-19","article-title":"Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals\u2019 Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1616-25","DOI":"10.1093\/infdis\/jiy065","article-title":"Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.","volume":"217","author":"J Beran","year":"2018","journal-title":"J Infect Dis."},{"key":"ref-21","article-title":"Pfizer Begins a Phase 1\/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine Pfizer: One of the world\u2019s premier biopharmaceutical companies."},{"key":"ref-22","article-title":"A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization"},{"key":"ref-23","article-title":"A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults"},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"7372-8","DOI":"10.1016\/j.vaccine.2007.08.014","article-title":"The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.","volume":"25","author":"P Wright","year":"2007","journal-title":"Vaccine."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1456-63","DOI":"10.1016\/S0264-410X(98)00108-X","article-title":"Maternal immunization against viral disease.","volume":"16","author":"J Englund","year":"1998","journal-title":"Vaccine."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1524-30","DOI":"10.1056\/NEJM199311183292102","article-title":"Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.","volume":"329","author":"J Groothuis","year":"1993","journal-title":"N Engl J Med."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"531-7","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.","volume":"102","year":"1998","journal-title":"Pediatrics."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"3171-7","DOI":"10.4049\/jimmunol.179.5.3171","article-title":"Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children.","volume":"179","author":"A Awomoyi","year":"2007","journal-title":"J Immunol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"571-82","DOI":"10.1172\/JCI75183","article-title":"TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization.","volume":"125","author":"M Caballero","year":"2015","journal-title":"J Clin Invest."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1542\/peds.110.2.e20","article-title":"Respiratory syncytial virus infection in Navajo and White Mountain Apache children.","volume":"110","author":"J Bockova","year":"2002","journal-title":"Pediatrics."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1398-408","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.","volume":"15","author":"K O'Brien","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"592-8","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.","volume":"342","author":"J McLellan","year":"2013","journal-title":"Science."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"946-58","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.","volume":"390","author":"T Shi","year":"2017","journal-title":"Lancet."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"e24-31","DOI":"10.1542\/peds.2014-2151","article-title":"Respiratory syncytial virus-associated mortality in hospitalized infants and young children.","volume":"135","author":"C Byington","year":"2015","journal-title":"Pediatrics."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"96-103","DOI":"10.1164\/rccm.201603-0658OC","article-title":"Mortality due to Respiratory Syncytial Virus. Burden and Risk Factors.","volume":"195","author":"S Geoghegan","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"358-64","DOI":"10.1093\/infdis\/jiy517","article-title":"Mortality Associated With Acute Respiratory Infections Among Children at Home.","volume":"219","author":"M Caballero","year":"2019","journal-title":"J Infect Dis."},{"key":"ref-37","article-title":"Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVaxTM for Prevention of RSV Disease in Infants via Maternal Immunization."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1791-9","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.","volume":"368","author":"M Blanken","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"256-62","DOI":"10.1016\/j.jaci.2010.05.026","article-title":"The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.","volume":"126","author":"E Sim\u00f5es","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"811-8","DOI":"10.1542\/peds.2013-0982","article-title":"Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.","volume":"132","author":"S Yoshihara","year":"2013","journal-title":"Pediatrics."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"29-38","DOI":"10.1164\/rccm.201609-1812OC","article-title":"Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.","volume":"196","author":"H Mochizuki","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2213-2600(18)30232-7","article-title":"RSV prevention in infancy and asthma in later life - Authors' reply.","volume":"6","author":"N Scheltema","year":"2018","journal-title":"Lancet Respir Med."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"820-2","DOI":"10.1097\/INF.0000000000001167","article-title":"The Impact of Respiratory Syncytial Virus Disease Prevention on Pediatric Asthma.","volume":"35","author":"M Caballero","year":"2016","journal-title":"Pediatr Infect Dis J."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"355-60","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome.","volume":"127","author":"J L\u00f6tvall","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"49-58","DOI":"10.1080\/1744666X.2019.1541737","article-title":"Post-viral atopic airway disease: pathogenesis and potential avenues for intervention.","volume":"15","author":"S Hussain","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"ref-46","article-title":"Novavax \u2013 Creating Tomorrow\u2019s Vaccines Today."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"e0119509","DOI":"10.1371\/journal.pone.0119509","article-title":"A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.","volume":"10","author":"S Lambert","year":"2015","journal-title":"PLoS One."},{"key":"ref-48","article-title":"Positive topline data from phase 2 older adult trial and path forward for RSV F vaccine programs","year":"2017"},{"key":"ref-49","article-title":"GSK Study Register."},{"key":"ref-50","article-title":"Respiratory syncytial virus vaccine enters clinical testing.","year":"2017"},{"key":"ref-51","article-title":"Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants"},{"key":"ref-52","article-title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants"},{"key":"ref-53","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.","volume":"61","author":"M Griffin","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"6147-53","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.","volume":"57","author":"G Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"23514-24","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).","volume":"281","author":"W Dall'Acqua","year":"2006","journal-title":"J Biol Chem."},{"key":"ref-56","article-title":"Safety, Tolerability, and Pharmacokinetics of MK-1654 in Infants (MK-1654-002)"},{"key":"ref-57","article-title":"RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months"},{"key":"ref-58","article-title":"Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children"},{"key":"ref-59","article-title":"Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV \u0394NS2\/\u03941313\/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age"},{"key":"ref-60","article-title":"Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46\/NS2\/N\/\u0394M2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age"},{"key":"ref-61","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz082","article-title":"The syndrome we agreed to call bronchiolitis.","author":"F Polack","year":"2019","journal-title":"J Infect Dis."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1347-55","DOI":"10.1093\/infdis\/jiy040","article-title":"Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.","volume":"217","author":"E McFarland","year":"2018","journal-title":"J Infect Dis."},{"key":"ref-63","article-title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age"},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"301-17","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.","volume":"25","author":"D Majhen","year":"2014","journal-title":"Hum Gene Ther."},{"key":"ref-65","article-title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals\u2019 RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults"},{"key":"ref-66","article-title":"A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV"},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"20822-7","DOI":"10.1073\/pnas.0806244105","article-title":"Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.","volume":"105","author":"S Bueno","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"2092-7","DOI":"10.1080\/21645515.2017.1334026","article-title":"A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.","volume":"13","author":"E Rey-Jurado","year":"2017","journal-title":"Hum Vaccin Immunother."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-610\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-610\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-610\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T07:07:17Z","timestamp":1694848037000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-610\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":68,"URL":"https:\/\/doi.org\/10.12688\/f1000research.18749.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.20539.r47662","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.20539.r47661","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-610\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.20539.r47661, Ralph A Tripp, Department of Infectious Diseases, University of Georgia, Georgia, USA, 02 May 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-610\/v1#referee-response-47661","order":0,"name":"referee-response-47661","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.20539.r47662, Giovanni Piedimonte, Center for Pediatric Research, Lerner Research Institute, The Cleveland Clinic, Cleveland, USA, 02 May 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-610\/v1#referee-response-47662","order":1,"name":"referee-response-47662","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by a grant from the Bill & Melinda Gates Foundation (to FPP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}